Live Operator Landscape
Bottom line for this section
The live operator landscape is the empirical proof that this venture has a path — 12+ named companies are operating compliantly under documented patient-specific 503A carve-outs as of May 2026 — but it is also proof that the user's 22-peptide menu is wildly out of step with what actually scales in this market.
Research
The US telehealth compounded-peptide market in May 2026 is in active, large-scale operation despite intensifying federal pressure — 70+ companies have received FDA warning letters since September 2025, but most major operators continue to sell. Eden ($229-329/mo for compounded semaglutide/tirzepatide plus a non-GLP-1 mix of NAD+, sermorelin, MIC+B12), Mochi Health ($278/mo all-in for compounded tirzepatide), MEDVi ($249-499/mo for injection + oral forms), Henry Meds ($197-397/mo), Noom Med (microdose program at $79 first month), Willow ($399/mo injection-only after pivoting away from oral), and Ro (now mostly brand Zepbound at $399-549/mo) remain live; Hims & Hers (NYSE: HIMS) was DOJ-referred Feb 6 2026 and settled with Novo Nordisk Mar 9 2026, exiting compounded GLP-1s and seeing Q1 2026 gross margin fall from 73% to 65% and a $92.1M net loss vs $49.5M net income YoY. The legitimate post-shortage path under 503A relies on documented patient-specific carve-outs (allergy to inactive ingredient like polysorbate-80, dose/route not commercially available such as microdose or oral, or clinically-different combination formulation with B12/niacinamide); cost savings does not qualify. A structural concentration risk has emerged: STAT News reported four medical groups (Beluga Health, OpenLoop, MD Integrations, Telegra) sit behind 30%+ of FDA-warned telehealth companies, meaning the choice of MD-network partner concentrates regulatory exposure more than any single operator decision.
Key facts
Eden Health (tryeden.com) sells compounded semaglutide at $149 first month then $229/mo and compounded tirzepatide at $249 first month then $329/mo, plus a broad non-GLP-1 menu: NAD+ injections ($186-246/mo), sermorelin (from $126 first month on 3-month plan), MIC+B12 ($106/mo on 3-month plan), and NAD+ face cream + nasal spray. Site disclaimer: 'The FDA does not review or approve any compounded medications for safety or effectiveness.'
Mochi Health (joinmochi.com) prices compounded injectable tirzepatide at $79 base membership + $199/mo medication = $278/mo all-in, with compounded semaglutide at $99/mo add-on. Site uses the MSO/PC tell verbatim: 'All professional medical services are provided by licensed physicians and clinicians affiliated with independently owned and operated professional practices.' Mochi is a named defendant in Eli Lilly's April 2025 lawsuit.
MEDVi (medvi.com) received FDA Warning Letter #721455 dated February 20, 2026 citing misbranding; marketing language 'falsely suggested the company compounded the semaglutide and tirzepatide it sold' and 'certain claims implied FDA approval or evaluation of compounded products.' MEDVi founder Matthew Gallagher publicly disputed receipt, claiming the flagged domain (medvi.io) was operated by an affiliate marketing agency.
Henry Meds (henrymeds.com) sells compounded injectable semaglutide $297/mo standard, $197/mo on 12-mo prepay, and compounded tirzepatide in ORAL TABLET form (not injection) — a key dose/route-not-commercially-available carve-out since FDA-approved tirzepatide is injection-only. Named Eli Lilly defendant.
Hims & Hers Health (NYSE: HIMS) was referred to the Department of Justice for investigation on February 6, 2026 by HHS General Counsel Mike Stuart. Novo Nordisk filed patent-infringement suit Feb 9 2026. Both matters resolved March 9 2026 — Novo voluntarily dismissed; Hims committed to stop advertising compounded GLP-1s, offer existing patients FDA-approved alternatives, and sell brand Wegovy/Ozempic at telehealth-market pricing. Hims stock climbed 40%+ on settlement.
Hims Q1 2026 financials concretely demonstrate the cost of exiting compounded GLP-1: revenue $608.1M (+4% YoY), gross margin compressed from 73% to 65%; net loss $92.1M vs net income $49.5M Q1 2025; adjusted EBITDA $44.3M from $91.1M; $33.5M restructuring charges including inventory write-downs.
On February 20, 2026, FDA issued warning letters to 30 telehealth companies (public March 3, 2026): MEDVi, Better Health Labs (dba Measured) — #721454 — Lovely Meds, Hello Cake, Kin Meds, GoodGirlRx, WeightCare, PharmaZee, Bliv Wellness, Belle Health, FitRX, BluefitMD, Viv Health, 24HrDoc. Companies had 15 days to respond or face 'seizure or injunction' threats.
STAT News reported March 2026 that four nationwide medical groups — Beluga Health, OpenLoop, MD Integrations, and Telegra — are affiliated with at least 30% of telehealth companies FDA has warned. STAT reported 'more than 70 telehealth companies warned by the FDA in the last six months.' Founder choice of MD-network partner concentrates regulatory exposure more than any single operator-level decision.
Eli Lilly filed lawsuits in April 2025 against Mochi Health, Fella & Delilah Health, Willow Health Services, and Henry Meds alleging false advertising, deceptive marketing, off-label cosmetic-weight-loss claims, and Corporate Practice of Medicine violations. Mochi's complaint specifically alleges Mochi switched patients to compounded tirzepatide with B12-style additives (niacinamide) and different doses at least five times in eight months.
U.S. District Judge Andre Birotte Jr. DISMISSED Eli Lilly's lawsuit against Willow Health on September 8, 2025 (without prejudice). The court found Lilly 'failed to show that any patients or physicians switched from its branded products to Willow Health's compounded alternatives' and that 'personalized' marketing terms were legally permissible. This reduces immediate litigation risk for Mochi/Fella/Henry but Lilly retains right to refile.
OFA v. FDA ruling May 7, 2025 (N.D. Texas) UPHELD FDA's decision to remove tirzepatide from the drug shortage list, concluding 'the FDA acted within its statutory authority.' Eliminated the broad shortage exception that enabled mass compounding of essentially-copy tirzepatide; operators must now invoke narrow patient-specific 503A carve-outs.
FDA April 1, 2026 clarification: 503A compounders may fill up to four prescriptions per calendar month for compounded GLP-1 products that are essentially copies without enforcement action. Compounded GLP-1 is 'essentially a copy' when it has the same API in similar strength (within 10%) and the same administration route. Three preserved patient-specific carve-outs: (1) documented allergy to an inactive ingredient (e.g., polysorbate-80), (2) clinical need for a dose strength or route not commercially available, (3) combination formulation with clinically-significant difference. Cost savings explicitly does NOT qualify.
Willow (startwillow.com) sells compounded tirzepatide as INJECTABLE ONLY at $399/mo (HSA/FSA eligible), having pivoted away from oral. Footer disclaimer: products 'are not approved by the U.S. Food and Drug Administration (FDA) and have not undergone clinical trials… are not substitutes for FDA-approved medications such as MOUNJARO, ZEPBOUND, Wegovy, or Ozempic.' Willow explicitly disclaims 'not approved for cosmetic weight loss.'
Noom Med launched a 'Microdose GLP-1Rx Program' March 31, 2026 at $79 (4-week intro) then $199/mo (12-week plan). Disclaimer: 'If your clinician feels compounded medications are clinically appropriate for you, any compounded medications are not approved by the FDA or reviewed for quality, safety or efficacy.' Standard GLP-1Rx Plus $149 first month then $299/mo. Ships to ~40 states.
Ro (ro.co) has substantially pivoted from compounded GLP-1 to brand Zepbound via direct Eli Lilly partnership. Sells 2.5 mg Zepbound vials $399/mo and 5 mg vials $549/mo, plus $39-149/mo membership. Compounded GLP-1 offerings (semaglutide, tirzepatide) still listed by comparison sites but Ro's primary positioning is now FDA-approved brand. Serves all 50 states.
Good Life Meds (goodlifemeds.com) sells one of the broadest non-GLP-1 peptide menus among compliant operators: NAD+ injections + nasal spray, sermorelin, MIC+B12, glutathione, B12, plus compounded tirzepatide (injectable + microdose + oral), compounded semaglutide, oral semaglutide, sexual health, and hair regrowth. NAD+ has no FDA-approved commercial equivalent, eliminating the 'essentially-a-copy' attack vector facing GLP-1s.
On April 15-16, 2026, FDA announced removal of 12 peptides from Category 2 pending PCAC review at meetings July 23-24, 2026 and February 2027. July 2026 review: BPC-157, KPV, TB-500, MOTs-C, Emideltide (DSIP), Semax, Epitalon. February 2027 review: GHK-Cu (injectable), Melanotan II, Cathelicidin (LL-37), Dihexa acetate, Mechano Growth Factor, PEG-MGF. Removal from Category 2 does NOT permit compounding — peptides remain in regulatory limbo. Tactus Health is positioned as the 'clean' compliant operator prescribing only sermorelin + PT-141.
State-level enforcement is intensifying. Alabama AG obtained TRO against Aurora IV & Wellness on November 10, 2025 alleging injection of patients with research-grade semaglutide/tirzepatide labeled 'not for human use.' Connecticut AG issued May 21, 2025 statewide notice that bulk compounding is no longer permitted post-shortage and 'generic Ozempic' terms violate CUTPA. Over 40 state AGs sent joint letter to FDA in 2025.
Payment processing is hostile: Stripe, PayPal, Square, and Boulevard 'often freeze accounts tied to peptide sales, even for legitimate telemedicine practices' and 'do not support GLP-1 sales — many medspas are learning this the hard way when their accounts are terminated without warning.' GLP-1s are now treated as a high-risk merchant category 'not unlike CBD, supplements, or online gambling.' Acquiring banks require LegitScript Healthcare Merchant Certification.
OpenLoop Health (the platform/medical group used by MEDVi among others) disclosed a January 2026 data breach affecting approximately 1.6 million patient records, with 68,160 confirmed affected individuals in Texas alone. Concentration risk on a single MD-network partner extends beyond regulatory exposure to data-breach exposure.
Tactus Health ships to all states except California and Mississippi as of 2026-05-22 (direct fetch of tactushealth.com). The geographic carve-out is itself a clue: California's July 1 2026 non-resident-PIC rule per §2 is the most plausible driver for the CA exclusion. Mississippi driver is not surfaced by Tactus publicly.
Tradeoffs
Compounded vs brand-only GLP-1 strategy
Compounded GLP-1 (Eden / Mochi / MEDVi / Henry / Willow model)
Pro: Lower COGS, larger gross margin (Hims' compounded margin was 73%); Pricing autonomy ($149-399/mo range vs $399-549/mo for brand); Can serve patients via patient-specific carve-outs (allergy, dose-route, combination); Faster product iteration
Con: FDA warning-letter risk demonstrated across 70+ operators since Sept 2025; Eli Lilly + Novo Nordisk private-litigation exposure; Payment processor freezes (Stripe/PayPal/Square reject the category); Banking is high-risk, requires LegitScript; State AG enforcement (Connecticut, Alabama precedents); DOJ referral risk (HHS referred Hims Feb 2026)
Brand-only (Hims post-March-2026 / Ro pivot / LillyDirect)
Pro: No FDA enforcement risk on the product itself; Mainstream payment processors will underwrite; Insurance reimbursement pathway available; Cleaner co-marketing with manufacturers
Con: Margin collapse — Hims Q1 2026 GM fell 73%→65%, $92.1M net loss vs $49.5M net income YoY; Higher COGS, lower contribution margin per subscriber; $33.5M restructuring charges in Hims' case; Manufacturer pricing power constrains pricing autonomy; Loses non-allergy / non-microdose / non-combination patient segments
Single-category specialty (GLP-1 only) vs multi-peptide platform
GLP-1-focused (Mochi, Fella, Henry, Willow, MEDVi)
Pro: Concentrated demand from largest weight-loss market segment; Marketing efficiency in one keyword space; Tighter clinical protocols
Con: Single point of regulatory failure if FDA tightens further; Direct manufacturer-litigation crosshairs; No diversification when GLP-1 enforcement intensifies
Multi-peptide platform (Eden, Good Life Meds)
Pro: Revenue diversification across NAD+, sermorelin, MIC+B12, sexual health, hair; NAD+ has no FDA-approved commercial equivalent → no 'essentially-a-copy' attack; Sermorelin is on the legally-compoundable list (Tactus Health uses it as flagship); Reduces single-category enforcement blast radius
Con: Higher operational complexity; Smaller per-category market vs GLP-1 wave; BPC-157/CJC-1295/Ipamorelin remain in Cat 2 / regulatory gray zone — risk if featured
"The live operator landscape is the empirical proof that this venture has a path — 12+ named companies are operating compliantly under documented patient-specific 503A carve-outs as of May 2026 — but it is also proof that the user's 22-peptide menu is wildly out of step with what actually scales in this market. Even the broadest live operators top out at 5-7 SKUs and the compliance-flagship operator (Tactus) sells only 2."
Recommendation
Build to the compliant pattern documented in Hims's 10-K (friendly-PC + MSO + 503A pharmacy partner + LegitScript-certified high-risk payment processor) but start narrower than any current operator: NAD+ injectable + topical GHK-Cu + branded Egrifta/Vyleesi/Scenesse where the FDA-approved indication overlaps your patient population. Avoid Beluga Health / OpenLoop / MD Integrations / Telegra as MD-network partners because they sit behind 30%+ of FDA-warned telehealth companies per STAT News; use a different MD network or build your own physician relationships. Treat the July 23-24 2026 PCAC outcome as the gating event for adding any Tier-2 wellness peptide (BPC-157, TB-4, KPV, MOTS-C, Epitalon, DSIP, Semax) — and do not add CJC-1295/Ipamorelin even after the PCAC because they were removed from Cat 2 in Sept 2024 with no further FDA review timeline.
Steel-manned counter
The strongest counter is that operators like Mochi ($278/mo all-in compounded tirzepatide, B12 combination carve-out) and Henry Meds (oral tirzepatide tablets, dose/route carve-out) are scaling and growing even as named Eli Lilly defendants — including post-warning-letter wave — and Hims itself returned to profit-positive guidance after exiting compounded GLP-1s (FY2026 $2.8-3.0B revenue guidance + $275-350M Adjusted EBITDA). A founder with a sophisticated MSA, documented patient-specific clinical-difference framing per Rx, and dual-MID payment architecture could replicate that posture with a broader menu than NAD+/GHK-Cu. The risk is concentration not breadth: Tactus Health's 2-peptide menu is one defensible posture but so is Eden's 5-7 SKU menu, and the operational evidence does not require launching at minimum breadth.
| Feature | Primary products | Pricing ($/mo) | Disclosed carve-out / posture | FDA actions | Eli Lilly defendant? | Status (May 2026) |
|---|---|---|---|---|---|---|
| Eden (tryeden.com) | Compounded sema + tirz; NAD+ inj/cream/nasal; sermorelin; MIC+B12; hair | Sema $229 / Tirz $329 / NAD+ $186-246 / sermorelin from $126 | Multi-peptide platform; disclaimer 'FDA does not review or approve any compounded medications' | None publicly named in Feb 2026 wave | No | LIVE |
| Mochi Health (joinmochi.com) | Compounded injectable sema + tirz with RD consults | $278 all-in (tirz: $79 base + $199 add-on); $178 for sema | MSO/PC structure; B12/niacinamide combination | None publicly named in Feb 2026 wave | Yes (Apr 2025) | LIVE |
| Henry Meds (henrymeds.com) | Compounded injectable semaglutide; compounded ORAL tablet tirzepatide | Sema $297 std / $197 12-mo prepay; Tirz $349 (oral) | Dose/route-not-commercially-available carve-out | Not in Feb 2026 wave | Yes (Apr 2025) | LIVE |
| Fella Health (fellahealth.com) | Tirz + sema (ambiguous); enclomiphene; rapamycin; NAD+; metformin | Sema $249-259 / Tirz $349-398; NAD+ $99; Metformin $45 | Men-targeted; HIPAA + LegitScript badges; pivot status unclear | Not in Feb 2026 wave | Yes (Apr 2025) | LIVE (ambiguous) |
| Willow (startwillow.com) | Compounded injectable tirzepatide only | Tirz $399 injection only | Explicit 'not for cosmetic weight loss' disclaimer | Not in Feb 2026 wave | Yes (Apr 2025) — DISMISSED Sep 8 2025 | LIVE |
| MEDVi (medvi.com) | Compounded sema + tirz: injection + oral tablet | Sema $179-299 / Tirz $349 inj / $249-499 oral | Injection + oral mix; dose/route carve-out via oral | FDA Warning Letter #721455 (Feb 20 2026); founder disputes | No | LIVE (under FDA scrutiny) |
| Hims & Hers (NYSE: HIMS) | EXITED compounded GLP-1; now brand Wegovy / Ozempic / Zepbound | Brand market rate (~$299-499) | Pivoted to brand-only after DOJ referral + Novo settlement | DOJ referred Feb 6 2026; Novo settled Mar 9 2026 | Yes (general) | EXITED compounded; brand co-promotion |
| Ro (ro.co) | Brand Zepbound vials; compounded still listed | $39-149 mem + $399 (2.5mg) / $549 (5mg) | Substantially pivoted to brand; all-50-states | Not in Feb 2026 wave | No (per public records) | LIVE — brand-primary |
| Noom Med (noom.com/med) | Compounded sema; brand options | Microdose $79/$199; std $149/$299 | Microdose framing (clinician-designed lower dose) | Not in Feb 2026 wave | No | LIVE — ~40 states |
| Good Life Meds (goodlifemeds.com) | Compounded tirz + sema + microdose + oral; NAD+ inj/spray; sermorelin; MIC+B12; sexual health; hair | GLP-1 pricing hidden on homepage | Multi-peptide platform; NAD+ has no FDA brand equiv | None publicly named | No | LIVE |
| Tactus Health (tactushealth.com) | Sermorelin + PT-141 ONLY (the two legally-compoundable peptides) | Not disclosed publicly | Cleanest legal posture — refuses BPC-157 / CJC-1295 / ipamorelin | None | No | LIVE — compliance-flagship positioning |
| Measured (Better Health Labs) | Compounded GLP-1s | Not publicly verified | Not disclosed | FDA Warning Letter #721454 (Feb 20 2026) | No | Under FDA scrutiny |
Likelihood → / Impact ↑
| State | Major operator coverage | State enforcement posture | Notable action / posture | Practical ship-to status |
|---|---|---|---|---|
| California | Ro, Found, Noom Med, Calibrate, WW Clinic, Eden, Mochi, Henry, MEDVi all serve CA | CPOM-strict state; medical board active | Willow Health dismissal heard in CA Federal Court (Judge Birotte, Sep 2025); James v. MEDVi early-stage CA complaint (Mar 2026) | Open for compliant operators; aggressive private litigation venue |
| Texas | Ro, Found, Noom Med, Calibrate, WW Clinic serve TX | Mixed — TX hosts FDA litigation but ND TX upheld FDA shortage delisting | OFA v. FDA decided in ND Texas (May 7 2025). OpenLoop breach affected 68,160 confirmed TX individuals | Open; data-breach exposure recognized |
| Florida | Ro, Found, Noom Med, Calibrate, WW Clinic serve FL | Active board of medicine; advertising rules under Ch 64B8 | No named telehealth peptide enforcement publicly identified | Open |
| New York | Ro, Found, Noom Med, Calibrate, WW Clinic serve NY | CPOM-strict; OPMC scrutiny of telehealth physicians | No named telehealth peptide enforcement publicly identified | Open; PC structure required |
| Connecticut | Ro, Found, Noom Med, Calibrate serve CT | MOST AGGRESSIVE state AG enforcement to date | CT AG May 21 2025 statewide notice + Triggered Brand settlement; CUTPA invoked; 'generic Ozempic' deceptive | Open but marketing language risk is highest in CT |
| Alabama | Ro, Found serve AL | AG-led criminal/civil enforcement against research-grade-as-pharma operators | Nov 10 2025: AG TRO + asset freeze against Aurora IV & Wellness | Open for compliant operators; AG actively pursuing bad actors |
| Pennsylvania | Ro, Found, Noom Med, Calibrate serve PA | Standard board oversight | No named telehealth peptide enforcement publicly identified | Open |
| Illinois | Ro, Found, Noom Med, Calibrate serve IL | CPOM enforcement present | No named telehealth peptide enforcement publicly identified | Open |
Open questions
Things this report could not resolve. Send these to your specific advisor.
Fella Health's current compounded-vs-brand status is ambiguous — site lists tirzepatide and semaglutide without explicit pricing or compounded/brand labeling.
Email this question to your lawyerFull named list of all 30 telehealth companies in the FDA Feb 20 2026 wave — only 14 named recipients confirmed across sources.
Email this question to your lawyerHims & Hers US-only revenue Q1 2026 segment breakdown not directly confirmed (verified total $608.1M).
Email this question to your lawyerMEDVi compounding pharmacy partner not disclosed in any source reviewed.
Email this question to your lawyer